ELGX Endologix Inc

Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that Robert Mitchell, President of Global Strategic Initiatives, is scheduled to present at the Jefferies 2011 Global Healthcare Conference in London.

Event: Jefferies 2011 Global Healthcare Conference

Date: Tuesday, September 27, 2011

Time: 5:00 p.m. GMT (12:00 p.m. ET)

An audio webcast of the Company's presentation will be available by visiting the investor relations section of Endologix's website at www.endologix.com. A replay of the presentation will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. The Nellix® Endovascular System and Ventana™ Fenestrated Stent Graft System are investigational devices. Additional information can be found on Endologix's Web site at www.endologix.com.

CONTACT: COMPANY CONTACT:
         Endologix, Inc.
         John McDermott, CEO
         (949) 595-7200
         www.endologix.com
         
         INVESTOR CONTACTS:
         The Ruth Group
         Nick Laudico (646) 536-7030
         Zack Kubow (646) 536-7020